New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. EisenhauerNational Cancer Institute of Canada-Clinical Trials Group, 10 Stuart Street, Queen's University, Kingston, Ontario, Canada. [email protected]P. TherasseGlaxoSmithKline Biologicals, Rixensart, BelgiumJan BogaertsEuropean Organisation for Research and Treatment of Cancer, Data Centre, Brussels, BelgiumLawrence H. SchwartzMemorial Sloan Kettering Cancer Center, New York, NY, USADaniel J. SargentMayo Clinic, Rochester, MN, USARobert C. FordJanet DanceyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USASusan G. ArbuckStephen J. GwytherEast Surrey Hospital, Redhill, Surrey, UKMargaret MooneyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USALarry RubinsteinDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USALalitha ShankarDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USALori E. DoddDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USARichard KaplanNational Cancer Research Network, Leeds, UKDenis LacombeEuropean Organisation for Research and Treatment of Cancer, Data Centre, Brussels, BelgiumJaco J. VerweijErasmus University Medical Center, Rotterdam, The Netherlands
2008en
ABI
Аннотация
Аннотация мавжуд эмас.
Идентификаторлар
Иқтибослар ва манбалар
2 та иқтибос0 та фойдаланилган манба